Prashant Kumar Navigating the transition from drug approval to market substitution requires a clear understanding of how regulatory bodies evaluate therapeutic equivalence. The FDA’s latest guidance on the topic gives drug sponsors a transparent view into how the agency assigns Orange Book codes. Understanding these principles is vital for biopharma executives, regulatory teams, and commercial strategists looking … Read more
Navigating the clinical trial landscape requires balancing groundbreaking innovation with extreme financial burden, particularly when manufacturing costs threaten to stall development. The FDA offers a formal pathway to recover direct costs for investigational drugs and devices without triggering allegations of premature commercialization, whereby the sponsor can get FDA’s approval to charge for its investigational drugs … Read more
Translating cutting-edge cell and gene therapies (CGTs) from early bench concepts to commercial realities presents a complex regulatory landscape. FDA’s latest FAQ guidance adds to its previous suggestions regarding regulatory interactions, chemistry, manufacturing, and controls (CMC), nonclinical evaluation, and clinical design. For sponsors navigating regulatory hurdles, this guidance provides an operational blueprint to clarify agency … Read more
Developing active immunotherapy products (ACTIMPs) has long presented a unique bioanalytical bottleneck because therapeutic efficacy relies on complex host immune responses rather than straightforward direct activity. For years, drug developers have wrestled with static legacy testing expectations that fail to accommodate multi-antigen vectors, cellular matrices, or patient-specific neoantigen vaccines. The FDA’s new guidance outlines a … Read more
Choosing between an ANDA (generic) and a 505(b)(2) application determines your development cost, timeline, and clinical burden. The FDA’s updated guidance, released this week, clarifies how regulators evaluate the applicability of either of these pathways to new applications. The two pathways are vastly different in their development programs and expected returns presenting a core financial … Read more
Traditional software validation frameworks are proving ill-equipped for the fluid, unpredictable nature of generative artificial intelligence in healthcare. As medical device developers navigate open-ended prompts, hallucination risks, and third-party foundation models, the FDA’s Center for Devices and Radiological Health (CDRH) has released a landmark discussion paper outlining a dedicated regulatory approach for GenAI-enabled devices. While … Read more
Over the years, the FDA has published several highly targeted series of iterations on formal PDUFA interactions, beginning with foundational frameworks under FDAMA in 2000, progressing through major updates in 2017 and 2018, and evolving into draft revisions in late 2023. The latest guidance released this week discusses important procedural and logistical preferences of the … Read more
Imagine scrolling through a slick betting app, placing a quick wager on an Oscar winner, and then sliding over to bet on whether a childhood cancer drug will pass its final clinical trial. This isn’t a speculative dystopian concept; it is the current reality offered by platforms like Kalshi and Polymarket, which now allow users … Read more
Enrolling patients in clinical trials has long been one of the steepest operational hurdles in medical innovation. For years, researchers have debated whether financial compensation serves as a necessary driver for recruitment or an unethical bribe that skews participant motivation. A recent study published in JAMA Internal Medicine provides crucial clarity on this long-standing dilemma. The data reveals … Read more
When senior FDA leadership published “America Must Address Early Clinical Development” on the official FDA Voices blog, industry stakeholders immediately take notice. However, beneath the bold rhetoric lies a familiar structural tension that has plagued recent regulatory communications: the conflation of executive vision with enforceable policy. Outlining an ambitious “Expedited IND Pilot” utilizing Qualified Research Institutions (QRIs) and rolling submissions, the agency framed the … Read more
